ProPhase Labs Inc (PRPH)

How to Take Advantage of moves in (PRPH) - Stock Traders Daily

Stock Traders Daily

Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength? - Yahoo Canada Shine On

Yahoo Canada Shine On

ProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo News Australia

Yahoo News Australia

ProPhase Labs: Hidden Gem With An AI Kicker (NASDAQ:PRPH) - Seeking Alpha

Seeking Alpha

ProPhase Labs (NASDAQ:PRPH) Rating Increased to Sell at StockNews.com - Defense World

Defense World

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - Yahoo Canada Shine On

Yahoo Canada Shine On

ProPhase Labs (PRPH) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Earnings call: ProPhase Labs outlines growth strategy and product potential - Investing.com

Investing.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant ... - GlobeNewswire

GlobeNewswire

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

GlobeNewswire Inc.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant ... - GlobeNewswire

GlobeNewswire

Reviewing ProPhase Labs (NASDAQ:PRPH) and Agile Therapeutics (NASDAQ:AGRX) - Defense World

Defense World

ProPhase Labs (PRPH) Scheduled to Post Earnings on Thursday - Defense World

Defense World

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Zacks Investment Research

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL - GlobeNewswire

GlobeNewswire

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Zacks Investment Research

ProPhase Labs, Inc. to Post Q1 2024 Earnings of ($0.15) Per Share, Diamond Equity Forecasts (NASDAQ:PRPH) - Defense World

Defense World

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

GlobeNewswire Inc.

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 ... - Yahoo Finance UK

Yahoo Finance UK

ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above Two Hundred Day Moving Average of $5.00 - Defense World

Defense World

ProPhase Labs Unveils Project ZenQ-AI

GlobeNewswire Inc.

ProPhase Labs advances cancer treatment with AI - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

Zacks Investment Research

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? - Yahoo Finance UK

Yahoo Finance UK

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test ... - GlobeNewswire

GlobeNewswire

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Yahoo Finance

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic ... - PR.com

PR.com

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

GlobeNewswire Inc.

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its ... - GlobeNewswire

GlobeNewswire

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

GlobeNewswire Inc.

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants ... - Yahoo Finance

Yahoo Finance

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

GlobeNewswire Inc.

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir - Yahoo Finance

Yahoo Finance

Sidus Space Appoints Bill White as Chief Financial Officer - Business Wire

Business Wire

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics - GlobeNewswire

GlobeNewswire

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts - Yahoo Finance

Yahoo Finance

ProPhase Labs Inc (PRPH) Reports Mixed Q3 Results Amid Strategic Transformations - Yahoo Finance

Yahoo Finance

ProPhase Labs hires Dr. Matthew Halpert to Drive Company's - GlobeNewswire

GlobeNewswire

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 - GlobeNewswire

GlobeNewswire

ProPhase Labs' Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome ... - Yahoo Finance

Yahoo Finance

Prophase Labs eyes 2024 launch of esophageal cancer test - BioWorld Online

BioWorld Online

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy - GlobeNewswire

GlobeNewswire

While insiders own 21% of ProPhase Labs, Inc. (NASDAQ:PRPH), individual investors are its largest shareholders with ... - Yahoo Finance

Yahoo Finance